Complete Response Submitted to U.S. FDA on Bayers Rivaroxaban for the Reduction of Secondary ...
10:07 EDT 8 Sep 2012 | LaMerie
Supplemental New Drug Application for Rivaroxaban to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome also resubmitted
Original Article: Complete Response Submitted to U.S. FDA on Bayers Rivaroxaban for the Reduction of Secondary ...
More From BioPortfolio on "Complete Response Submitted to U.S. FDA on Bayers Rivaroxaban for the Reduction of Secondary ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
